Literature DB >> 7657540

Murine model of ocular infection by a human biovar of Chlamydia trachomatis.

J A Whittum-Hudson1, T P O'Brien, R A Prendergast.   

Abstract

PURPOSE: A human biovar of Chlamydia trachomatis was used to develop a murine model of ocular chlamydial infection. The inbred mouse model will allow detailed immunologic studies during ocular infection, and use of a human biovar for infection may aid in identification of appropriate vaccine strategies against chlamydial infections.
METHODS: BALB/c, C3H/HeN, and C57B1/6J mice (n = 5 to 10 mice/group) were topically infected in the conjunctiva with C serovar of C. trachomatis. The effects were tested of single and repeated infection with 5000 inclusion-forming units (IFU) in 5 microliters and different inoculum doses. Conjunctival surfaces of both eyes were swabbed for microbiologic signs (isolation culture or direct fluorescent antibody staining) of infection over 4 to 6 weeks. Conjunctivae were removed for histopathologic study, and lymphocytes from draining cervical lymph nodes and spleens were tested for chlamydia-specific proliferative responses. Serum was obtained from all mice and tested for anti-chlamydial antibodies.
RESULTS: BALB/c and C3H/HeN mice developed dose-dependent microbiologic, histopathologic, and immunologic evidence of ocular infection. Eyes of mice were culture-positive from day 7 through at least day 21, with the peak of infection at days 10 to 14 after infection. Histopathologically, the development of conjunctival subepithelial mononuclear infiltration, exudate, and loss of goblet cells occurred within 1 week. Dose-dependent lymphoproliferative responses to whole chlamydial elementary bodies were observed; anti-chlamydial antibody was detected by immunoblotting only in infected mice.
CONCLUSIONS: Several strains of inbred mice are susceptible to human chlamydial biovars and may provide a useful alternative disease model in which to study the immunopathogenesis of ocular chlamydial infection and test of vaccine candidates derived from clinically relevant human biovars.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657540

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

2.  Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis.

Authors:  S J Rasmussen; L Eckmann; A J Quayle; L Shen; Y X Zhang; D J Anderson; J Fierer; R S Stephens; M F Kagnoff
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

3.  Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.

Authors:  Ingrid S Ganda; Qian Zhong; Mirabela Hali; Ricardo L C Albuquerque; Francine F Padilha; Sandro R P da Rocha; Judith A Whittum-Hudson
Journal:  Int J Pharm       Date:  2017-05-22       Impact factor: 5.875

4.  Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.

Authors:  J U Igietseme; J L Portis; L L Perry
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies.

Authors:  Alexander Badamchi-Zadeh; Paul F McKay; Martin J Holland; Wayne Paes; Andrzej Brzozowski; Charles Lacey; Frank Follmann; John S Tregoning; Robin J Shattock
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

6.  The effect of infectious dose on humoral and cellular immune responses in Chlamydophila caviae primary ocular infection.

Authors:  Ana Filipovic; Ehsan Ghasemian; Aleksandra Inic-Kanada; Ivana Lukic; Elisabeth Stein; Emilija Marinkovic; Radmila Djokic; Dejana Kosanovic; Nadine Schuerer; Hadeel Chalabi; Sandra Belij-Rammerstorfer; Marijana Stojanovic; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.